Lambert Eaton myasthenic syndrome (LEMS): cancer management
Evidence-based neurology checklist on lambert eaton myasthenic syndrome (lems): cancer management: Investigations for cancer Computed tomography (CT) scan chest Positron emission tomography (PET) scan: if CT is negative Also see Neurochecklist: “Paraneoplastic neurological syndromes: cancer…
Investigations for cancer
- Computed tomography (CT) scan chest
- Positron emission tomography (PET) scan: if CT is negative
- Also see Neurochecklist: “Paraneoplastic neurological syndromes: cancer screening”
Paraneoplastic risk assessment
DELTA-P scoring items
DELTA-P based cancer screening strategy items
References
- Titulaer MJ, Lang B, Verschuuren JJGM. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet 2011; 10:1098-1107.
- Sabater L, Titulaer M, Saiz A, Verschuuren J, Gure AO, Graus F. SOX1 antibodies are makers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 2008; 70:924-928.
- Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton mutagenic syndrome (LEMS) tumour association score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol 2011; 29:902-908.
- Weimer MB, Wong J. Lambert-eaton myasthenic syndrome. Curr Treat Options Neurol 2009; 11:77-84.
- Kesner VG, Oh SJ, Dimachkie MM, Barohn RJ. Lambert-Eaton myasthenic syndrome. Neurol Clin 2018; 36:379-394.
